PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20662320-0	2010	Effects of silybinin, CYP3A4 and P-glycoprotein inhibitor in vitro, on the bioavailability of loratadine in rats.	Loratadine	94-104	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	33-47	
19230596-8	2008	It suggested that roxithromycin may improve the oral bioavailability of loratadine by reducing first-pass metabolism of loratadine most likely mediated by P-glycoprotein (P-gp) and/or cytochrome P450 (CYP) 3A4 in the intestine and/or liver.	Loratadine	72-82	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	155-169	
19230596-8	2008	It suggested that roxithromycin may improve the oral bioavailability of loratadine by reducing first-pass metabolism of loratadine most likely mediated by P-glycoprotein (P-gp) and/or cytochrome P450 (CYP) 3A4 in the intestine and/or liver.	Loratadine	72-82	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	171-175	
19230596-8	2008	It suggested that roxithromycin may improve the oral bioavailability of loratadine by reducing first-pass metabolism of loratadine most likely mediated by P-glycoprotein (P-gp) and/or cytochrome P450 (CYP) 3A4 in the intestine and/or liver.	Loratadine	120-130	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	155-169	
19230596-9	2008	In conclusion, the presence of roxithromycin significantly enhanced the bioavailability of loratadine in rats, it may be due to inhibition of both CYP 3A4-mediated metabolism and P-gp in the intestine and/or liver by the presence of roxithromycin.	Loratadine	91-101	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	179-183	
20945138-8	2010	The enhanced bioavailability of loratadine may be due to inhibition both cytochrome P450 3A4-mediated metabolism and the efflux pump P-glycoprotein (P-gp) in the intestine and/or liver by the presence of prednisolone.	Loratadine	32-42	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	133-147	
20945138-8	2010	The enhanced bioavailability of loratadine may be due to inhibition both cytochrome P450 3A4-mediated metabolism and the efflux pump P-glycoprotein (P-gp) in the intestine and/or liver by the presence of prednisolone.	Loratadine	32-42	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	149-153